GTC Biotherapeutics (fka GTCB)

[Biowatch]

Neose Announces Presentation of GlycoPEGylated Factor VIIa Data at the American Society of Hematology Annual Meeting
Wednesday December 12, 4:28 pm ET

HORSHAM, Pa.--(BUSINESS WIRE)--Neose Technologies, Inc. (Nasdaq GM:NTEC) announced that two posters were presented regarding preclinical data for GlycoPEGylated recombinant Factor VIIa at the American Society of Hematology 49th Annual Meeting and Exposition in Altanta, Georgia. GlycoPEGylated Factor VIIa, currently in Phase I, is being developed by Novo Nordisk A/S under a license from Neose.

The posters are titled:

* Platelet-Dependent Activity of GlycoPEGylated rFVIIa (co-authored by Novo Nordisk and Neose)
* Activity and Regulation of Long-Acting Factor VIIa Analogs (co-authored by Novo Nordisk and The University of Texas Health Center)

The presentations are available on the Neose corporate website at: http://phx.corporate-ir.net/phoenix.zhtml?c=60494&p=irol-presentations

http://biz.yahoo.com/bw/071212/20071212006088.html?.v=1